-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's etcamah did not reach the primary progression-free survival end in the Serena-4 trial.

Zhitongcaijing·09/11/2026 20:25:09
Listen to the news
AstraZeneca's etcamah did not reach the primary progression-free survival end in the Serena-4 trial.